Eliem Therapeutics has raised $60 million to advance treatments for neuronal excitability disorders. The series B round equips Eliem to take its lead c
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,